New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory ...
A biopsy of a woman's cancer seems to have triggered an immune response against the tumour, putting her into remission ...
Li is Princeton's Robert F. Goheen Professor in the Humanities and a professor of creative writing at the Lewis Center for ...
UCB will pay up to $2.2bn for Candid Therapeutics, betting on cizutamig and the wider T-cell engager rush in autoimmune disease.
The newly identified species lived side-by-side with a close relative at the same New Mexico site – and their contrasting jaw ...
Since my first readings (among the most important, Albert Schweitzer on leprosy in Lambaréné, Gabon), my idea was to protect ...
Canada’s National Research Council boldly advertises itself as “advancing mission-driven science and innovation” — to ...
INSTI, Tenofovir-Free Regimen DOR/ISL Gains FDA Approval for HIV This fixed-dose, 2-drug combination is a once-daily, ...
New modeling suggests a global threshold may have been crossed in 2024, though its significance varies enormously by region.
Symptoms such as fatigue, loss of appetite, altered sleep, and social withdrawal are often treated as inconvenient side ...
Recursion Pharmaceuticals' AI-driven Recursion OS platform shows strong potential but has yet to demonstrate a clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results